The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada

PURPOSE: Fluoro-2-deoxyglucose positron-emission tomography (FDG-PET/CT) is now considered a standard investigation for the staging of new cases of stage III NSCLC. However, there is not published level 3 evidence demonstrating the impact of FDG-PET/CT on appropriate therapy in this setting. Using r...

Descripción completa

Detalles Bibliográficos
Autores principales: Beers, Craig A., Pond, Gregory R., Wright, James R., Tsakiridis, Theodoros, Okawara, Gordon S., Swaminath, Anand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482027/
https://www.ncbi.nlm.nih.gov/pubmed/37681028
http://dx.doi.org/10.3389/fonc.2023.1210945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482027/
https://www.ncbi.nlm.nih.gov/pubmed/37681028
http://dx.doi.org/10.3389/fonc.2023.1210945

Ejemplares similares